Member Info for Ralphiebabe

PYC)

Date Time Trade Prc Volume Buy/Sell Bid Ask Value

08-Nov-24 16:35:29 70.00 6,023,170 Unknown* 0.65 0.75 4m O

08-Nov-24 15:20:29 0.669 120,000 Sell* 0.65 0.75 802.80 O

Think they got price wrong at 70p, showing as £4 million trade?

Unless that’s what sp will be on Monday, wishful thinking.

Worth about £42,000!

Link of Peter Sergeant with Proactive, I have not viewed yet.

https://www.proactiveinvestors.co.uk/companies/news/1060124/physiomics-marks-record-year-with-expanding-consultancy-and-personalized-medicine-initiatives-1060124.html

One of Physiomics collaborations.

Ankyra Therapeutics Announces First Visceral Tumor Patient Dosed in Phase 1 ANCHOR Clinical Trial of ANK-101, an Anchored Interleukin-12 (IL-12)

https://www.businesswire.com/news/home/20241105939527/en/Ankyra-Therapeutics-Announces-First-Visceral-Tumor-Patient-Dosed-in-Phase-1-ANCHOR-Clinical-Trial-of-ANK-101-an-Anchored-Interleukin-12-IL-12

https://www.physiomics.co.uk/contract-award-9/

From awhile ago.

Some positive testimonials.

A great hire! Mark is a tremendous asset! Wishing you the best moving forwards!

Mark is a diligent information scientist

Mark was a very personable colleague who I worked with on computational modelling of the link between cardiac ion channel modulation and effects on the cardiac action potential. He was a very effective advocate of the work and particularly good at communicating his area of expertise in a way that we biologists could understand

Mark is an extremely capable scientist who has now made the transition from wet to computational biology. Therefore, he is one of the few scientists who covers the full spectrum of Systems Biology with experience in cell biology and computer modelling

Hope they obtaining new contracts.

https://www.linkedin.com/posts/physiomics-plc_bioeurope-bioeurope2024-drugdevelopment-activity-7259506957470830592-9aXi?utm_source=share&utm_medium=member_desktop

What a fantastic first day at hashtag#BioEurope! 🤩 Hayley Close and our new Head of Quantitative Pharmacology and Data Science, Mark Davies, had a busy day yesterday connecting with BioPharma innovators and discussing how Physiomics plc’ expertise in modelling and data science can make a real difference in drug development.

We’re ready for Day 2 and looking forward to more great conversations about how our growing services in modelling, simulation and biostatistics can help tackle your development challenges.

Is also attending Bio Europe this week

Mark DaviesMark Davies

• 3rd+ • 3rd+

Head of Quantitative Pharmacology and Data Science, providing data science consulting and modelling and simulation services to the biopharma communityHead of Quantitative Pharmacology and Data Science, providing data science consulting and modelling and simulation services to the biopharma community

3d • 3 days ago

Follow

Really excited to be attending BIO-Europe, next week in Stockholm, Sweden, where the event marks 30 years of facilitating partnerships. If you are there, do send me a message to arrange a meeting, look forward to making new connections! Informa Connect

Activate to view larger image,

BIO-Europe 2024

Is mentioned on Physiomics LinkedIn, there is also picture of woman if you scroll down, is this new scientist?

https://www.linkedin.com/company/physiomics-plc/people/

More info on Mark Davies

A scientist working in a Business Development role using my experiences gained from the past twenty years in pharmaceutical drug discovery and development. My mission is to help in identifying (and explaining) how questions and challenges can be addressed through better use of diverse data sources and modelling. Interested in helping to enhance cross-functional and cross-domain working, by helping to develop a common working language.

https://www.linkedin.com/in/mark-davies-33b2521/?originalSubdomain=uk

Exciting to see the programme we worked on with Numab Therapeutics AG moving into the clinic! 🎉 Looking forward to what’s next!

View organization page for Numab Therapeutics AG, graphic

Numab Therapeutics AG

Numab is pleased to announce the start of a Phase 1 clinical trial evaluating NM32, a next generation tri-specific immuno-oncology therapeutic targeting the receptor tyrosine kinase-like orphan receptor 1 (ROR1) and the T-cell receptor associated antigen CD3. The low molecular weight of NM32 allows to efficiently achieve higher tumor concentrations than larger immunoglobulin G molecules, the current standard format for CD3 engagers.

https://www.linkedin.com/posts/physiomics-plc_exciting-to-see-the-programme-we-worked-on-activity-7257803517342445568-yPTg

🎉 Last week’s hashtag#ENASymp24 offered us a fantastic opportunity to share our latest work! 🎉

We were excited to present our new poster, "Data analysis and model evaluation of chemotherapy-induced neutropenia – results from the PARTNER trial," which showcases results from our PARTNER trial, led by the Portsmouth Technology Trials Unit. This observational study gathered crucial data from prostate cancer patients treat with docetaxel, helping us validate our personalised dosing tool.

Early findings are promising – analysis of trial data confirms the ability of the tool to predict levels and timing of episodes of hashtag#neutropenia associated with use of docetaxel and which can lead to serious side effects for patients. In addition, there is potential for our tool to be used to predict the effect of GCSF, a drug commonly used to increase white blood cell count during chemotherapy.

Proud to showcase our impact on cancer research and precision medicine. 🙌 We'll be sharing the full poster on our website soon, so stay tuned!

https://www.linkedin.com/posts/physiomics-plc_enasymp24-neutropenia-personaliseddosing-ugcPost-7258053424653504512-0oUF?utm_source=share&utm_medium=member_desktop

Debull, Physiomics gave RNS of completion of Partner study on 9th Jan 2023, similar details as KingH link.

https://www.physiomics.co.uk/completion-of-partner-study/

For latest X’s(tweets) from conference see. #ENASymp24.

No message from Physiomics as usual.

Hope there’s positive news with results for Partner study.

If you’ll be there, be sure to catch Léa Sta, PhD’s poster presentation on Thursday 24th October (Poster Number 240), featuring results from our PARTNER study – our exciting step towards a personalised oncology dosing tool. 💡

A quantitative pharmacology lead develops strategies for quantitative analyses and experiments, and works to impact drug development strategies and decisions. They may also mentor early career scientists.

Quantitative pharmacology is important for drug discovery because it helps validate targets, optimize the development of lead compounds, and scale compounds to humans.

Has been with Physiomics for years, she was Project leader, has now posted she starting new position at Physiomics as Quantitative Pharmacology Lead.

https://www.linkedin.com/posts/frances-brightman-11bb6446_im-happy-to-share-that-im-starting-a-new-activity-7253781803050635265-Gy-F?utm_source=share&utm_medium=member_desktop

Thought it was Lea Sta presenting info, unless it’s been reorganised.

📊 Léa Sta, PhD will also be presenting our latest data from the PARTNER study, supporting the development of our personalised oncology dosing tool.

https://www.linkedin.com/posts/physiomics-plc_enasymp24-cancerresearch-oncology-activity-7247257957548142593-gR0E?utm_source=share&utm_medium=member_desktop

Directors wages page 19

https://www.physiomics.co.uk/wp-content/uploads/2024/10/Annual-Report-and-Financial-Statements-For-the-Year-Ended-30-June-2024_Website-1.pdf

Article about cancer and blood test.

https://www.theguardian.com/science/2024/oct/05/government-to-fund-120-blood-test-that-could-detect-12-most-common-cancers

Will presentation be similar as previous years going over what was announced in the results, or will there be some breaking news to get the sp motoring?